MA45845B1 - Combinaisons de l'imételstat et du vénétoclax destinées au traitement de la leucémie aigüe myéloblastique - Google Patents

Combinaisons de l'imételstat et du vénétoclax destinées au traitement de la leucémie aigüe myéloblastique

Info

Publication number
MA45845B1
MA45845B1 MA45845A MA45845A MA45845B1 MA 45845 B1 MA45845 B1 MA 45845B1 MA 45845 A MA45845 A MA 45845A MA 45845 A MA45845 A MA 45845A MA 45845 B1 MA45845 B1 MA 45845B1
Authority
MA
Morocco
Prior art keywords
imetelstat
treatment
venetoclax
combinations
inhibitor
Prior art date
Application number
MA45845A
Other languages
English (en)
Other versions
MA45845A (fr
Inventor
Fei Huang
Joshua J. RUSBULDT
Aleksandra RIZO
Original Assignee
Geron Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Geron Corporation filed Critical Geron Corporation
Publication of MA45845A publication Critical patent/MA45845A/fr
Publication of MA45845B1 publication Critical patent/MA45845B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Control Of Indicators Other Than Cathode Ray Tubes (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Apparatus For Radiation Diagnosis (AREA)
  • Developing Agents For Electrophotography (AREA)
  • Glass Compositions (AREA)
  • Photoreceptors In Electrophotography (AREA)

Abstract

La présente invention concerne un traitement d'association pour des cancers hématologiques. Plus spécifiquement, une combinaison d'un inhibiteur de télomérase et d'un inhibiteur de Bcl-2 est utile dans le traitement de cancers hématologiques, comprenant la LMA. Dans certains modes de réalisation, l'inhibiteur de télomérase est l'imételstat ou l'imételstat sodium et l'inhibiteur de Bcl-2 est ABT-199.
MA45845A 2016-08-02 2017-07-28 Combinaisons de l'imételstat et du vénétoclax destinées au traitement de la leucémie aigüe myéloblastique MA45845B1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662370018P 2016-08-02 2016-08-02
EP16197293.0A EP3318276A1 (fr) 2016-11-04 2016-11-04 Combinaisons d'un inhibiteur de la télomérase et d'un inhibiteur du bcl-2 destinées au traitement des cancers hématologiques
US201662422738P 2016-11-16 2016-11-16
EP17748613.1A EP3493812B1 (fr) 2016-08-02 2017-07-28 Combinaisons de l'imételstat et du vénétoclax destinées au traitement de la leucémie aigüe myéloblastique
PCT/US2017/044348 WO2018026646A1 (fr) 2016-08-02 2017-07-28 Traitement d'association pour cancers hématologiques

Publications (2)

Publication Number Publication Date
MA45845A MA45845A (fr) 2019-06-12
MA45845B1 true MA45845B1 (fr) 2025-08-29

Family

ID=57226888

Family Applications (1)

Application Number Title Priority Date Filing Date
MA45845A MA45845B1 (fr) 2016-08-02 2017-07-28 Combinaisons de l'imételstat et du vénétoclax destinées au traitement de la leucémie aigüe myéloblastique

Country Status (28)

Country Link
US (2) US11278561B2 (fr)
EP (3) EP3318276A1 (fr)
JP (3) JP7016856B2 (fr)
KR (3) KR102854375B1 (fr)
CN (2) CN116327954A (fr)
AU (2) AU2017305950B2 (fr)
CA (2) CA3217021A1 (fr)
CL (1) CL2019000228A1 (fr)
DK (1) DK3493812T3 (fr)
ES (1) ES2941462T3 (fr)
FI (1) FI3493812T3 (fr)
HR (1) HRP20230300T1 (fr)
HU (1) HUE061471T2 (fr)
IL (2) IL264451B2 (fr)
LT (1) LT3493812T (fr)
MA (1) MA45845B1 (fr)
MD (1) MD3493812T2 (fr)
MX (2) MX395085B (fr)
NZ (1) NZ750191A (fr)
PL (1) PL3493812T3 (fr)
PT (1) PT3493812T (fr)
RS (1) RS64074B1 (fr)
SG (1) SG11201900883UA (fr)
SI (1) SI3493812T1 (fr)
SM (1) SMT202300108T1 (fr)
UA (1) UA124935C2 (fr)
WO (1) WO2018026646A1 (fr)
ZA (1) ZA201900939B (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9375485B2 (en) 2012-12-07 2016-06-28 Geron Corporation Use of telomerase inhibitors for the treatment of myeloproliferative disorders and myeloproliferative neoplasms
EP3318276A1 (fr) * 2016-11-04 2018-05-09 Janssen Biotech, Inc. Combinaisons d'un inhibiteur de la télomérase et d'un inhibiteur du bcl-2 destinées au traitement des cancers hématologiques
JP7316261B2 (ja) 2017-07-28 2023-07-27 ジェロン・コーポレーション 骨髄異形成症候群の治療方法
KR20200108301A (ko) * 2018-01-10 2020-09-17 리커리엄 아이피 홀딩스, 엘엘씨 벤즈아미드 화합물
KR20250074692A (ko) 2018-11-29 2025-05-27 제론 코포레이션 골수이형성 증후군을 치료하는 방법
KR20220004669A (ko) * 2019-04-29 2022-01-11 이뮤노젠 아이엔씨 항-cd123 면역접합체를 포함하는 치료적 조합물
IL299205A (en) * 2020-07-17 2023-02-01 Geron Corp Subcutaneous telomerase inhibitor preparations and methods of using them
WO2022159760A1 (fr) * 2021-01-22 2022-07-28 The Regents Of The University Of California Méthodes de traitement et d'atténuation d'un cancer
US12447163B2 (en) * 2021-07-16 2025-10-21 Jazz Pharmaceuticals Therapeutics, Inc. Liposomal formulations of Bcl inhibitors
EP4463151A4 (fr) 2022-01-19 2025-10-01 Univ Northwestern Agents ciblant la transcriptase inverse de la télomérase (tert) pour traiter le cancer et sensibiliser des cellules cancéreuses à une thérapie génotoxique
CN114949230B (zh) * 2022-06-13 2024-12-06 厦门大学附属第一医院 一种预防和/或治疗急性髓系白血病的联合用药物组合物及其应用
CN118593709B (zh) * 2024-05-28 2025-05-23 湖南大学 Fasn抑制剂的新用途、化合物、化合物的新用途

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5583016A (en) 1994-07-07 1996-12-10 Geron Corporation Mammalian telomerase
US5958680A (en) 1994-07-07 1999-09-28 Geron Corporation Mammalian telomerase
US5776679A (en) 1994-07-07 1998-07-07 Geron Corporation Assays for the DNA component of human telomerase
CN1317291C (zh) 1999-09-10 2007-05-23 杰龙公司 寡核苷酸n3′→p5′硫代氨基磷酸酯,其合成及应用
PL1667522T3 (pl) 2003-09-09 2018-06-29 Geron Corporation Zmodyfikowane oligonukleotydy do hamowania telomerazy
WO2006113470A2 (fr) 2005-04-15 2006-10-26 Geron Corporation Procede pour traiter un cancer grace a l'inhibition combinee d'activites de proteasome et de telomerase
WO2006113426A2 (fr) 2005-04-15 2006-10-26 Geron Corporation Traitement de cancer par inhibition combinee des activites de la telomerase et de la tubuline
WO2006124904A2 (fr) 2005-05-16 2006-11-23 Geron Corporation Traitement du cancer par inhibition combinee de telomerase et d'activites hsp90
LT2898887T (lt) 2006-10-30 2018-11-12 Geron Corporation Telomerazės inhibitoriaus ir gemcitabino derinys vėžio gydymui
US8785409B2 (en) 2007-01-30 2014-07-22 Geron Corporation Compounds having anti-adhesive effects on cancer cells
EP2134364B1 (fr) 2007-03-09 2013-02-13 Geron Corporation Traitement de carcinomes avec une combinaison d'inhibiteurs de voie egf et de telomerase
EP3029154B1 (fr) 2008-10-17 2017-10-04 Geron Corporation Procédé d'identification de la sensibilité d'un patient à une thérapie d'inhibition de la télomérase
WO2011017096A2 (fr) * 2009-08-04 2011-02-10 Mayo Foundation For Medical Education And Research Procédés de traitement de cancers hématologiques
TW201427664A (zh) * 2012-11-02 2014-07-16 Pharmacyclics Inc Ｔｅｃ家族激酶抑制劑佐劑療法
JP6359028B2 (ja) 2012-11-30 2018-07-18 ジェロン・コーポレーションＧｅｒｏｎ Ｃｏｒｐｏｒａｔｉｏｎ テロメラーゼ阻害剤を用いて細胞増殖性障害を処置するための診断マーカー
US9200327B2 (en) 2012-11-30 2015-12-01 Geron Corporation Diagnostic markers for treating cell proliferative disorders with telomerase inhibitors
RS59363B1 (sr) 2012-12-07 2019-11-29 Geron Corp Upotreba inhibitora telomeraze imetelstata za lečenje mijelofibroze
US9375485B2 (en) 2012-12-07 2016-06-28 Geron Corporation Use of telomerase inhibitors for the treatment of myeloproliferative disorders and myeloproliferative neoplasms
EA030957B1 (ru) * 2013-03-14 2018-10-31 Оникс Терапьютикс, Инк. Дипептидные и трипептидные эпоксикетонные ингибиторы протеазы
WO2014160071A1 (fr) * 2013-03-14 2014-10-02 St. Jude Children's Research Hospital Procédés et compositions pour le traitement de cancers dépendants à la glutamine
HUE042792T2 (hu) 2013-11-06 2019-07-29 Mayo Found Medical Education & Res Eljárások és anyagok hematológiai, rosszindulatú betegségek kezelésére
US11034757B2 (en) * 2014-06-09 2021-06-15 Biomed Valley Discoveries, Inc. Combination therapies using agents that target tumor-associated stroma or tumor cells and tumor vasculature
US9635050B2 (en) 2014-07-23 2017-04-25 Cisco Technology, Inc. Distributed supervised architecture for traffic segregation under attack
EP3198276B1 (fr) 2014-09-24 2023-09-20 Exscientia GmbH Monocouche de cmsp ou de cellules de la moelle osseuse et leurs utilisations
EP3318276A1 (fr) * 2016-11-04 2018-05-09 Janssen Biotech, Inc. Combinaisons d'un inhibiteur de la télomérase et d'un inhibiteur du bcl-2 destinées au traitement des cancers hématologiques
JP7316261B2 (ja) 2017-07-28 2023-07-27 ジェロン・コーポレーション 骨髄異形成症候群の治療方法

Also Published As

Publication number Publication date
CA3032118A1 (fr) 2018-02-08
AU2023229592A1 (en) 2023-10-05
HRP20230300T1 (hr) 2023-05-12
PT3493812T (pt) 2023-03-30
MD3493812T2 (ro) 2023-05-31
KR20190049708A (ko) 2019-05-09
JP2019523277A (ja) 2019-08-22
AU2017305950A1 (en) 2019-02-21
CL2019000228A1 (es) 2019-05-17
RS64074B1 (sr) 2023-04-28
IL264451B2 (en) 2024-01-01
EP3493812B1 (fr) 2023-01-04
SMT202300108T1 (it) 2023-05-12
NZ750191A (en) 2023-03-31
CN109641002B (zh) 2022-10-18
KR102515378B1 (ko) 2023-03-29
BR112019002025A2 (pt) 2019-05-14
IL305332A (en) 2023-10-01
MX2019001315A (es) 2019-07-01
JP2024166290A (ja) 2024-11-28
KR20230047206A (ko) 2023-04-06
EP3318276A1 (fr) 2018-05-09
US11278561B2 (en) 2022-03-22
CN109641002A (zh) 2019-04-16
ZA201900939B (en) 2023-04-26
WO2018026646A1 (fr) 2018-02-08
UA124935C2 (uk) 2021-12-15
IL264451A (en) 2019-02-28
KR102854375B1 (ko) 2025-09-04
MX395085B (es) 2025-03-24
MA45845A (fr) 2019-06-12
JP7016856B2 (ja) 2022-02-07
KR20250134002A (ko) 2025-09-09
EP4218768A1 (fr) 2023-08-02
ES2941462T3 (es) 2023-05-23
JP2022145948A (ja) 2022-10-04
FI3493812T3 (fi) 2023-04-14
US20180036336A1 (en) 2018-02-08
CA3217021A1 (fr) 2018-02-08
PL3493812T3 (pl) 2023-05-08
EP3493812A1 (fr) 2019-06-12
HUE061471T2 (hu) 2023-07-28
IL264451B1 (en) 2023-09-01
DK3493812T3 (da) 2023-04-11
LT3493812T (lt) 2023-04-11
CA3032118C (fr) 2023-12-12
MX2022010466A (es) 2022-09-19
CN116327954A (zh) 2023-06-27
SG11201900883UA (en) 2019-02-27
SI3493812T1 (sl) 2023-05-31
US20220168333A1 (en) 2022-06-02
AU2017305950B2 (en) 2023-06-22

Similar Documents

Publication Publication Date Title
MA45845B1 (fr) Combinaisons de l'imételstat et du vénétoclax destinées au traitement de la leucémie aigüe myéloblastique
CL2021000704A1 (es) Anticuerpos contra proteína alfa reguladora de señal y métodos de uso. (divisional de solicitud 668-2019)
MX2021015545A (es) Moduladores de cot y metodos de uso de estos.
EP3934645A4 (fr) Utilisation du catequentinib (anlotinib) en combinaison avec une chimiothérapie standard ou une immunothérapie standard pour le traitement du cancer
CO2022004797A2 (es) Anticuerpos anti-klk7, anticuerpos anti-klk5, anticuerpos multiespecíficos anti-klk5/klk7 y métodos de uso
CL2021001260A1 (es) Anticuerpos anti-sirpa humanizados
DE602004031372D1 (de) Nachweis von staphylococcus
EA201170288A1 (ru) Оксабициклогептаны и оксабициклогептены, их получение и применение
CL2022001540A1 (es) Uso de inhibidores de atr en combinación con inhibidores de parp.
MA46988A1 (fr) Formulation liquide d'anticorps anti-tnf alpha
EA202192394A1 (ru) Ингибиторы пути передачи сигнала notch и их применение для лечения рака
MA31265B1 (fr) Traitement du cancer au moyen de l'il-18 humaine combinee a un anticorps anti-cd20
CL2021003071A1 (es) Activación de explosivos en agujeros
JP1811128S (ja) グラフィカルユーザーインターフェース
MA38656A1 (fr) Combinaisons pour le traitement du cancer comprenant un inhibiteur de la kinase mps-1 et un inhibiteur de la mitose
MY147790A (en) Stable emulsion composition
JP1811130S (ja) グラフィカルユーザーインターフェース
MX2021011736A (es) Composiciones desodorantes.
EA200970518A1 (ru) Способы лечения злоупотребления алкоголем, хронического алкоголизма и алкогольной зависимости
SE0100176L (sv) Användning av en Zwitterjonisk tensid tillsammans med en anjonisk eterinnehållande tensid som friktionsnedsättande medel
PL1973514T3 (pl) Emulsja typu alkohol w oleju zawierająca sól wielowartościowego metalu
MD1459Y (ro) Aplicarea compusului 1,10-fenantrolină în calitate de inhibitor al dezvoltării cancerului la viţă de vie
MA44558A1 (fr) Dérivé du glucagon, conjugué de celui-ci, composition le comprenant et utilisation thérapeutique de celui-ci
FR3063906B1 (fr) Utilisation de l'oleoresine de copaifera dans les pathologies de la prostate
FR3044669B1 (fr) Composition pvc presentant une adhesion amelioree aux surfaces